A detailed history of Hgk Asset Management Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Hgk Asset Management Inc holds 33,611 shares of ABBV stock, worth $5.9 Million. This represents 1.25% of its overall portfolio holdings.

Number of Shares
33,611
Previous 38,250 12.13%
Holding current value
$5.9 Million
Previous $6.56 Million 1.17%
% of portfolio
1.25%
Previous 1.28%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$163.84 - $199.33 $760,053 - $924,691
-4,639 Reduced 12.13%
33,611 $6.64 Million
Q2 2024

Aug 06, 2024

BUY
$154.79 - $180.76 $116,247 - $135,750
751 Added 2.0%
38,250 $6.56 Million
Q1 2024

May 13, 2024

SELL
$159.82 - $182.1 $658,937 - $750,798
-4,123 Reduced 9.91%
37,499 $6.83 Million
Q4 2023

Feb 13, 2024

SELL
$137.6 - $154.97 $120,812 - $136,063
-878 Reduced 2.07%
41,622 $6.45 Million
Q3 2023

Oct 20, 2023

SELL
$133.59 - $154.65 $327,562 - $379,201
-2,452 Reduced 5.45%
42,500 $6.34 Million
Q2 2023

Aug 02, 2023

BUY
$132.51 - $164.9 $502,875 - $625,795
3,795 Added 9.22%
44,952 $6.06 Million
Q1 2023

Apr 28, 2023

BUY
$144.61 - $166.54 $356,463 - $410,521
2,465 Added 6.37%
41,157 $6.56 Million
Q4 2022

Feb 14, 2023

SELL
$138.31 - $165.87 $137,341 - $164,708
-993 Reduced 2.5%
38,692 $6.25 Million
Q3 2022

Oct 18, 2022

SELL
$134.21 - $153.93 $230,975 - $264,913
-1,721 Reduced 4.16%
39,685 $5.33 Million
Q2 2022

Jul 29, 2022

SELL
$137.62 - $174.96 $133,216 - $169,361
-968 Reduced 2.28%
41,406 $6.34 Million
Q1 2022

May 04, 2022

SELL
$131.98 - $163.75 $1.37 Million - $1.71 Million
-10,415 Reduced 19.73%
42,374 $6.87 Million
Q4 2021

Feb 01, 2022

SELL
$107.43 - $135.93 $298,762 - $378,021
-2,781 Reduced 5.0%
52,789 $7.15 Million
Q3 2021

Oct 28, 2021

BUY
$106.4 - $120.78 $1.27 Million - $1.44 Million
11,943 Added 27.38%
55,570 $5.99 Million
Q2 2021

Jul 30, 2021

SELL
$105.21 - $117.21 $93,636 - $104,316
-890 Reduced 2.0%
43,627 $4.91 Million
Q1 2021

Apr 15, 2021

SELL
$102.3 - $112.62 $180,354 - $198,549
-1,763 Reduced 3.81%
44,517 $4.82 Million
Q4 2020

Jan 08, 2021

BUY
$80.49 - $108.67 $65,277 - $88,131
811 Added 1.78%
46,280 $4.96 Million
Q3 2020

Nov 05, 2020

SELL
$85.91 - $100.83 $1.86 Million - $2.18 Million
-21,613 Reduced 32.22%
45,469 $3.98 Million
Q2 2020

Aug 10, 2020

SELL
$73.37 - $98.18 $1.05 Million - $1.41 Million
-14,320 Reduced 17.59%
67,082 $6.59 Million
Q1 2020

Apr 28, 2020

SELL
$64.5 - $97.79 $257,097 - $389,790
-3,986 Reduced 4.67%
81,402 $6.2 Million
Q4 2019

Jan 27, 2020

SELL
$72.13 - $90.25 $598,823 - $749,255
-8,302 Reduced 8.86%
85,388 $7.56 Million
Q3 2019

Nov 13, 2019

BUY
$62.98 - $75.72 $5.41 Million - $6.5 Million
85,878 Added 1099.31%
93,690 $7.09 Million
Q3 2019

Oct 24, 2019

SELL
$62.98 - $75.72 $3.6 Million - $4.32 Million
-57,118 Reduced 87.97%
7,812 $739,000
Q2 2019

Jul 23, 2019

BUY
$65.7 - $83.98 $3.85 Million - $4.92 Million
58,618 Added 928.68%
64,930 $4.72 Million
Q1 2019

May 07, 2019

SELL
$77.14 - $90.79 $106,453 - $125,290
-1,380 Reduced 17.94%
6,312 $509,000
Q4 2018

Jan 31, 2019

SELL
$77.85 - $96.01 $15,569 - $19,202
-200 Reduced 2.53%
7,692 $709,000
Q3 2018

Oct 29, 2018

BUY
$88.91 - $98.84 $88,554 - $98,444
996 Added 14.44%
7,892 $0
Q2 2018

Aug 08, 2018

BUY
$89.78 - $106.23 $4,129 - $4,886
46 Added 0.67%
6,896 $639,000
Q1 2018

May 08, 2018

SELL
$92.01 - $123.21 $90,629 - $121,361
-985 Reduced 12.57%
6,850 $648,000
Q4 2017

Feb 08, 2018

SELL
$89.56 - $98.21 $37,167 - $40,757
-415 Reduced 5.03%
7,835 $758,000
Q3 2017

Nov 13, 2017

SELL
$69.85 - $89.22 $5,588 - $7,137
-80 Reduced 0.96%
8,250 $733,000
Q2 2017

Aug 10, 2017

BUY
N/A
8,330
8,330 $604,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Hgk Asset Management Inc Portfolio

Follow Hgk Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hgk Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hgk Asset Management Inc with notifications on news.